Ghana

Tuberculosis profile

Population 2018: 30 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>44 (21–75)</td>
<td>148 (72–251)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>8.6 (4.1–15)</td>
<td>29 (14–49)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence**</td>
<td>0.87 (0.41–1.5)</td>
<td>2.9 (1.4–5)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (4.8–19)</td>
<td>36 (16–64)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>4.8 (2.3–8.1)</td>
<td>16 (7.7–27)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases: 1.3% (1–1.6)
Previously treated cases: 16% (14–19)

TB case notifications, 2018

Total new and relapse: 13,874
- % tested with rapid diagnostics at time of diagnosis: 60%
- % with known HIV status: 93%
- % pulmonary: 92%
- % bacteriologically confirmed***: 66%
- % children aged 0–14 years: 6%
- % women: 30%
- % men: 64%

Total cases notified: 14,289

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 32% (19–65)
TB patients facing catastrophic total costs, 2016: 64% (61–68)
TB case fatality ratio (estimated mortality/estimated incidence), 2018: 39% (14–68)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive: 2,509 (19%)
- on antiretroviral therapy: 1,155 (46%)

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance***
- New cases: 93%
- Previously treated cases: 100%

Laboratory-confirmed cases**

Patients started on treatment**

MDR/RRTB: 231, XDR-TB: 1

MDR/RRTB: 147, XDR-TB: 1

MDR/RRTB cases tested for resistance to second-line drugs: 68

Treatment success rate and cohort size

New and relapse cases registered in 2017: 85% (14,121)
Previously treated cases, excluding relapse, registered in 2017: 82% (429)
MDR/RRTB cases started on second-line treatment in 2016: 82% (77)
XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged <5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions): 20

Funding source: 13% domestic, 47% international, 40% unfunded

Ranges represent uncertainty intervals
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
** Includes cases with unknown previous TB treatment history

Generated: 2019-10-27
Data: www.who.int/tb/data